DOI: 10.26717/BJSTR.2017.01.000255
Corresponding author:
Jacqueline Sidman, The Sidman Institute, University Tower, 4199 Campus Drive, Suite 550, Irvine, California, 92612, USAReceived: July 21, 2017; Published: August 07, 2017
To view the Full Article Peer-reviewed Article PDF
The goal of this pilot study was to evaluate psychometric testing to establish objective assessments for treating depression and co-morbid anxiety. Clients of The Sidman Institute were asked to take the BDI-II and BAI before and after three therapy sessions. Short-Term Sidman Hypnotherapy (STSH), independent of antidepressants, resulted in significant improvement by Wilcoxon analysis of BDI-II (Z=3.264, p=0.0011) and BAI (Z=3.233, p=0.0013) with large effect sizes (>0.9). Rumination-associated symptoms decreased significantly, and retrospective followup with previous clients indicated no relapse from one to three years post therapy, further indicating treatment effectiveness.
Abstract| Introduction| Method| Results| Discussion| Authors’ Contributions| Funding| Acknowledgement| References|
International Association of Landscape Archaeology, Czech Glass Society, Czech Republic
Department of Chemistry, Semenov Institute of Chemical Physics, USSR Academy of Sciences, Moscow, Russia
Pharmaco-kinetics, dynamics and Drug Metabolism, Touro College of Pharmacy, USA
Professor of Nuclear Medicine, Faculty of Medicine and Surgery, University of Milan, Milan, Italy
Associate Professor at Department of Breast and Thyorid Surgey, Chongqing General Hospital, China